Nuclear-Based Labeling of Cellular Immunotherapies: A Simple Protocol for Preclinical Use.

IF 3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI:10.1007/s11307-024-01923-z

Alessia Volpe, Serge K Lyashchenko, Vladimir Ponomarev

引用次数: 0

Abstract

Labeling and tracking existing and emerging cell-based immunotherapies using nuclear imaging is widely used to guide the preclinical phases of development and testing of existing and new emerging off-the-shelf cell-based immunotherapies. In fact, advancing our knowledge about their mechanism of action and limitations could provide preclinical support and justification for moving towards clinical experimentation of newly generated products and expedite their approval by the Food and Drug Administration (FDA).Here we provide the reader with a ready to use protocol describing the labeling methodologies and practical procedures to render different candidate cell therapies in vivo traceable by nuclear-based imaging. The protocol includes sufficient practical details to aid researchers at all career stages and from different fields in familiarizing with the described concepts and incorporating them into their work.

Abstract Image

查看原文本刊更多论文

细胞免疫疗法的核基标记：临床前使用的简单方案。

利用核成像技术标记和跟踪现有和新兴的细胞免疫疗法被广泛用于指导现有和新出现的现成细胞免疫疗法临床前阶段的开发和测试。事实上，增进我们对其作用机理和局限性的了解，可以为新产品的临床前实验提供支持和理由，并加快食品药品管理局（FDA）对其的审批。在这里，我们为读者提供了一份即用协议，描述了通过核成像技术追踪体内不同候选细胞疗法的标记方法和实用程序。该方案包含足够的实用细节，可帮助各个职业阶段和不同领域的研究人员熟悉所描述的概念，并将其融入自己的工作中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.